Infliximab Pricing in International Economic Evaluations in Inflammatory Bowel Disease to Inform Biologic and Biosimilar Access Policies: A Systematic Review
Background. Policies mandating the use of lower cost biosimilars in patients with inflammatory bowel disease (IBD) have created concerns for patients who prefer their original biologic. Purpose. To inform the cost-effectiveness of biosimilar infliximab treatment in IBD by systematically reviewing th...
Main Authors: | Naazish S. Bashir, Avery Hughes, Wendy J. Ungar |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2023-02-01
|
Series: | MDM Policy & Practice |
Online Access: | https://doi.org/10.1177/23814683231156433 |
Similar Items
-
An Assessment of the Validity and Reliability of the Pediatric Child Health Utility 9D in Children with Inflammatory Bowel Disease
by: Naazish S. Bashir, et al.
Published: (2021-04-01) -
Under the Umbrella of Clinical Pharmacology: Inflammatory Bowel Disease, Infliximab and Adalimumab, and a Bridge to an Era of Biosimilars
by: Zvonimir Petric, et al.
Published: (2022-08-01) -
Anti-Drug Antibodies in Patients with Inflammatory Bowel Diseases Treated with Biosimilar Infliximab: A Prospective Cohort Study
by: Anna Pękala, et al.
Published: (2021-06-01) -
Discontinuation of infliximab treatment in patients with inflammatory bowel disease who retransitioned to originator and those who remained on biosimilar
by: Rosanne W. Meijboom, et al.
Published: (2023-09-01) -
Monitoring a Mandatory Nonmedical Switching Policy from Originator to Biosimilar Infliximab in Patients with Inflammatory Bowel Diseases: A Population-Based Cohort Study
by: Anat Fisher, et al.
Published: (2023-01-01)